Bibliografía del artículo
1. Pizzo PA. Considerations for the prevention of infectious complications in patient with cancer. Rev Infect Dis 1989; 11 (Suppl. 7):S1551-63.
2. Zinner SH. Treatment and prevention of infections in immunocompromised hosts. In: Gorbach SL, Bartlett JG, Blacklow NR, editors. Infectious Diseases, 2
nd edition. WB Saunders Company, Philadelphia.
3. Cruciani M. Antibacterial prophylaxis. Int J Antimicrob Agents 2000; 16:123-5.
4. Kerr KG. The prophylaxis of bacterial infections in neutropenic patients. J Antimicrob Chemother 1999; 44:587-91.
5. Van der Waaij D, Berghuis-de Vries JM, Lekkerker-van der Wees JEC. Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. J Hyg 1971; 69:405-11.
6. EORTC International Antimicrobial Therapy Project Group: Cotrimoxazole in the prevention of infection in neutropenic patients. J Infect Dis 1984; 150:372-9.
7. Cruciani M, Rampazzo R, Malena M et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996; 23:795-805.
8. Rotstein C, Mandell LA, Goldberg N. Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta-analysis. Current Oncology 1997; 4 suppl 2:2-7.
9. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol. 1998;16:1179-87.
10. Cruciani M, Malena M, Bosco O, Nardi S, Serpelloni G, Mengoli C. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003; 21:4127-37.
11. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 1998; 41 (Suppl. D):13-24.
12. Oppheneim BA, Hartley JE, Lee W et al. Outbreak of coagulase-negative staphylococcus highly resistant to ciprofloxacin in a leukemia unit. Br Med J 1989; 299:294-7.
13. Kotilainen P, Nikoskelainen J, Huovinen P. Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. J Infect Dis 1990; 161:41-4.
14. Bochud PY, Eggiman Ph, Calandra Th. et al. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18:25-31.
15. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002; 34:1524-9.
16. O'Grady NP, Alexander M, Dellinger EP et al. Guidelines for the prevention of intravascular catheter-related infections Clin Infect Dis 2002; 35:1281-307.
17. Razonable RR, Litzow MR, Khaliq Y et al. Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 2002; 34:1469-74.
18. Guglielmo BJ, Graff L, Linker C et al. Emergence of fluoroquinolone-resistant viridans streptococci associated with levofloxacin prophylaxis in neutropenic cancer patients. Abstracts of the Infectious Diseases Society of America 40
th annual meeting. Chicago, October 24-27, 2002 (Abstr. 19).
19. Jones RN, Pfaller MA. Potencies of newer fluoroquinolones against Viridans group
Streptococci isolated in 637 cases of bloodstream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): beyond Canada! Antimicrob Agents Chemother 2000; 44:2922-3.
20. Kaneko A, Sasaki J, Shimadzu M et al. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci. J Antimicrob Chemother 2000; 45:771-5.
21. Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 2001 ; 32 (suppl. 1):S9-15.
22. Prabhu RM, Elliott MA, Patel R . Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible
Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation. Clin Infect Dis 2004; 38:1043-1045.
23. Reuter S, Sigge A, Bommer M et al. Moxifloxacin-prophylaxis during neutropenia in patients with hemato-oncological malignancies. Abst. K-1540. 45
th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16-19, 2005.
24. Minenko SV, Dmitrieva NV, Sokolova EN, Zhukov NV, Ptushkin VV. Efficacy of moxifloxacin (Avelox) in prophylaxis of infection in patients with profound neutropenia. Antibiot Khimioter 2004;49:26-31.
25. Kern WV, Andrioff E, Oethinger M et al. Emergence of fluoroquinolone-resistant
Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994 ; 36:681-7.
26. Cometta A, Calandra T, Bille J et al.
Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330:1240-1 (letter).
27. Carratalá J, Fernández Sevilla A, Tubau F. Emergence of quinolone-resistant
Escherichia coli in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20:557-60.
28. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of
Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24:111-8.
29. Martino R, Subira M, Altes A et al. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity. Acta Haematol 1998; 99:206-11.
30. Nucci M. Resistant bacteria in stem cell transplant recipients. Rev Bras Hematol Hemoter 2002; 24:220-227.
31. Gómez L, Garau J, Estrada C, et al . Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant
Escherichia coli. Cancer 2003; 97:419-24.
32. Delarive P, Baumgarter JD, Glauser MP et al. Evaluation de la prophylaxie antibiotique chez les patients neutropeniques avec hemopathie maligne. Scweizerische Medizinische Wonchenschrift 2000; 130:1837-44.
33. De Bock R, Cometta A, Kern W et al. Incidence of single agent gram-negative bacteremias in neutropenic cancer patients in EORTC-IATG trials of empirical therapy for febrile neutropenia. 41
st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 2001 (Abstr. L-773).
34. Reuter S, Kern WV, Sigge A, Dohner H, Marre R, Kern P, Von Baum H. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005; 40:1087-93.
35. Cruciani M. Malena M, Rampazzo R et al. A cost-effectiveness analysis of prophylaxis in granulocytopenic patients. 36
th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996 (abs. N22).
36. The GIMEMA infection Program. Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 1991; 115:7-12.30.
37. Messori A, Trippoli S, Tendi E. Related G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation. J Clin Pharm Ther 1996; 21:57-63.
38. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer. N Engl J Med. 2005; 353:977-987.
39. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353:988-998.
40. Baden LR. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 2005; 353:1052-1054.
41. Gilbert DN, Kohlhepp SJ, Slama KA, et al. Phenotypic resistance of
Staphylococcus aureus, selected
Enterobacteriaceae and
Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin and trovafloxacin. Antimicrob Agents Chemother 2001; 45:883-92.
42. Polk RE, Johnson CK, McClish D, Wenzel RP, Edmond MB. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004; 15:39:497-503.
43. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142:979-95.
44. Karp JE, Merz WG, Hendricksen C, et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1987; 106:1-7.
45 Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-51.